Digital Health and Therapeutics
Accelerator Network

COPD360Net’s Mission is to support the development and adoption of novel digital health tools, medical devices and therapeutics that treat COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease.

In order to advance the development of new medicines, or the repurposing of existing drugs, a new approach is needed. COPD360Net is designed to facilitate, review, and expedite clinical trials for new therapies, medical devices, and digital health tools. In addition, COPD360Net is focused on implementation science – facilitating discovery to delivery.

Why COPD360Net?

While important strides have been made in improving the care for those with COPD, the last regulatory approval of a new mechanism of action therapeutic in COPD was in 2011, and drug development remains focused on individuals with moderate to advanced airflow limitation (GOLD 2-4).

In order to advance the development of new medicines, or the repurposing of existing drugs, a new approach is needed. COPD360Net is designed to facilitate, review, and expedite clinical trials for new therapies and digital health tools. In addition, COPD360Net is focused on implementation science – facilitating discovery to delivery.

Ultimately, the network will serve as an accelerator to speed innovation through patient-centered evidence generation and enabling clinical adoption.

What is COPD360Net?

COPD360Net is a network of core COPD Foundation accredited centers and networks, experts in the field of COPD and related lung disease, and relevant subject matter experts (including a Health Economist assessing Patient preferences and Valuation of the COPDF pipeline, a psychosocial expert studying cognitive impairment in chronic disease, and Primary Care physicians).

COPD360Net is governed by a Steering Committee of clinical lead expert representatives from participating centers, key content experts, and people with COPD and caregivers. The initial pipeline will be selected by the Steering Committee in partnership with the relevant subject-matter experts and the COPD Foundation’s Community Engagement Committee (CenCo), a diverse patient and caregiver committee.

The goals for COPD360Net are to:

Accelerate the adoption and reimbursement of digital health tools
Accelerate the development of novel therapies, including promising repurposed or shelved molecules
Innovate clinical trial designs: target specific COPD sub populations, use new endpoints, and take a mostly remote digital trials approach
Translate trial findings and patient preference into practice to inform optimal care delivery and reimbursement

Seeking funds for a platform study in young "Pre-COPD"

One of the studies COPD360Net is focused on conducting is a platform trial in young patients with non-obstructive chronic bronchitis. We currently seek partners to fund this critical study that aims to generate evidence on commonly prescribed medications used to treat this highly symptomatic population.

A call to action to investigators, funding agencies, industry, and regulators to initiate treatment trials for these populations who are currently being treated without evidence has recently been published in the American Journal of Respiratory and Critical Care Medicine.

All potential proceeds from COPD360Net will be used to support the COPD Foundation mission.

COPD360Net Steering Committee Members

Brad Drummond, MD (EXECUTIVE COMMITTEE)
Head of COPD360Net Digital Health and Therapeutic Pipeline Working Group
Associate Professor
University of North Carolina at Chapel Hill
Jerry Krishnan, MD, PhD (EXECUTIVE COMMITTEE)
Head of COPD360Net Care Delivery Science Working
Professor of Medicine and Public Health Associate & Vice Chancellor for Population Health Sciences
University of Illinois at Chicago
Chicago, IL
Wilson D. Pace, MD (EXECUTIVE COMMITTEE)
Co-Lead of Primary Care and Integrated Practice Working Group
American Academy of Family Physicians
Chief Medical Officer, DARTNet
Jean Rommes, PhD (EXECUTIVE COMMITTEE)
Head of COPD360Net Patient and Caregiver Engagement Working Group
Patient Representative
West Des Moines, IA
Juan P. Wisnivesky, MD, DrPH (EXECUTIVE COMMITTEE)
Co-Lead of Primary Care and Integrated Practice Working Group
Society of General Internal Medicine
Professor, Department of Medicine, Icahn School of Medicine at Mount Sinai
Surya Bhatt, MD
Associate Professor
University of Alabama, Birmingham
Gerard Criner, MD
Chair and Professor, Thoracic Medicine and Surgery
Temple University
Philadelphia, PA
MeiLan Han, MD, MS
Professor of Medicine in the Division of Pulmonary and Critical Care
University of Michigan
Ann Arbor, MI

Karin Hoth, PhD, ABPP
Associate Professor of Psychiatry
University of Iowa Carver College of Medicine
Iowa City, IA
Ravi Kalhan, MD
Professor of Medicine (Pulmonary and Critical Care) and Preventive Medicine (Epidemiology)
Northwestern University
Chicago, IL
Jill Ohar, MD
Professor, Pulmonary, Critical Care, Allergy, and Immunologic Medicine
Wake Forest Baptist Health
Winston-Salem, NC
Fernando Martinez, MD
Bruce Webster Professor of Internal Medicine, Professor of Medicine, Professor of Genetic Medicine
Cornell University
New York, NY
Richard Mularski, MD, MSHS, MCR
Professor of Health Systems Science, KP Bernard J. Tyson School of Medicine
Clinical Professor of Medicine, OHSU
The Center for Health Research
Kaiser Permanente Northwest, Portland, OR
Julia F. Slejko, PhD
Assistant Professor
Pharmaceutical Health Services Research
University of Maryland School of Pharmacy
Baltimore, MD
Robert (Bob) Wise, MD
Professor of Medicine
Johns Hopkins University
Baltimore, MD

COPD360Net Partners and Collaborators:

ENA Respiratory

The COPD Foundation and ENA Respiratory have partnered to accelerate the development of INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, to be utilized by people with chronic lung diseases. INNA-051 becomes the second pipeline asset for COPD360Net. Click here to learn more.

Exploristics

The COPD Foundation and Exploristics are collaborating to utilize Exploristics’ innovative study simulation software platform KerusCloud to establish a more efficient and smarter data-driven approach to study design and protocol development. Click here to learn more.

Renovion

The COPD Foundation and Renovion have partnered to accelerate the development of a novel nebulized therapy, ARINA-1, for the treatment of excessive airway mucus and inflammation in individuals with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis (CF) bronchiectasis. ARINA-1 becomes the first pipeline asset for COPD360Net. Click here to learn more.

Savana

The COPD Foundation and Savana, an international medical company that has developed a scientific methodology that applies Artificial Intelligence (AI) to unlock clinical value embedded within the free text of (EHRs), are partnering to accelerate innovative clinical research into COPD. Learn more here about the COPD Foundation- Savana partnership.

Who can I contact about COPD360Net?

For more information about COPD360Net, please contact us at COPD360net@copdfoundation.org.